Crisaborole

Drug Profile

Crisaborole

Alternative Names: AN-2728; Crisaborole ointment 2%; Eucrisa; PF-06930164

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anacor Pharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Heterocyclic bicyclo compounds; Nitriles; Nonsteroidal anti-inflammatories; Organic boron compounds; Phenyl ethers; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Atopic dermatitis
  • Suspended Psoriasis

Most Recent Events

  • 29 Aug 2017 Pfizer plans a phase I trial in Healthy volunteers (NCT03260595)
  • 02 Aug 2017 Pfizer plans a phase II trial for Atopic dermatitis in Canada (NCT03233529)
  • 31 Jul 2017 Phase-II clinical trials in Atopic dermatitis in Canada (Topical) (NCT03233529)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top